Allergy to host KOL webinar on VLP Peanut

RNS Number : 9077K

Allergy Therapeutics PLC

07 September 2021

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics to host KOL webinar on VLP Peanut vaccine candidate

7 September 2021 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, today announces that it will host a webinar entitled 'VLP Peanut; a next generation peanut allergy immunotherapy', on Friday 17 September 2021 at 14.00 BST, 09.00 EDT.

The webinar will include an introduction from Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, and a feature presentation by key opinion leader (KOL), Dr. Mo Shamji, Reader in Immunology & Allergy at Imperial College London.

Dr. Shamji will summarise the findings of the Group's ex vivo VLP Peanut 001 biomarker study which, as announced on 3 August 2021, showed the hypoallergenic potential of the vaccine candidate, due to enter the clinic in Q1 2022.

Dr. Matt Heath, Principal Scientist at Allergy Therapeutics, will also provide an overview presentation on the Group's novel virus-like particle (VLP) technology.

The presentation will be followed by a live Q&A session and details can be accessed on the Group's website at https://www.allergytherapeutics.com/investors/results-reports-and-presentations/ . A replay of both will be made available on the website shortly after the event.

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Carina Jurs

[e-mail]

Stern Investor Relations, Inc.

[phone]

Christina Tartaglia

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m² of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

 

END

 

 

NRAUNVKRASUKRAR